Published in J Allergy Clin Immunol on June 01, 2004
Clinical efficacy and immune regulation with peanut oral immunotherapy. J Allergy Clin Immunol (2009) 3.91
Regulatory T cells in asthma. Immunity (2009) 2.00
Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization. J Allergy Clin Immunol (2011) 1.93
Analysis of complex patterns of human exposure and immunity to Schistosomiasis mansoni: the influence of age, sex, ethnicity and IgE. PLoS Negl Trop Dis (2010) 1.28
Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov (2009) 1.10
Signaling through Fc gamma RIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med (2007) 1.09
IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. Immunol Lett (2009) 1.08
Mechanisms of allergen-specific immunotherapy. Clin Transl Allergy (2012) 1.06
Nonhuman primate models of asthma. J Exp Med (2005) 1.05
Human regulatory T cells: a unique, stable thymic subset or a reversible peripheral state of differentiation? Immunol Lett (2007) 1.05
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest (2010) 1.03
Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J (2015) 1.03
T-cell responses induced by allergen-specific immunotherapy. Clin Exp Immunol (2010) 0.94
Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med (2009) 0.94
Tolerizing allergic responses in the lung. Mucosal Immunol (2010) 0.88
Consensus Guidelines on Practical Issues of Immunotherapy-Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol (2006) 0.87
Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol (2012) 0.87
Tolerance induction after specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A in children. Clin Exp Immunol (2010) 0.87
Insulin-like growth factor-2 enhances functions of antigen (Ag)-specific regulatory B cells. J Biol Chem (2014) 0.86
Intralymphatic immunotherapy. World Allergy Organ J (2015) 0.86
Chemokines in onchocerciasis patients after a single dose of ivermectin. Clin Exp Immunol (2005) 0.85
Cross-reactivity in Grasses: Biochemical Attributes Define Exemplar Relevance. World Allergy Organ J (2012) 0.85
Human IgG4: a structural perspective. Immunol Rev (2015) 0.85
How safe are the biologicals in treating asthma and rhinitis? Allergy Asthma Clin Immunol (2009) 0.84
Mechanisms of Heightened Airway Sensitivity and Responses to Inhaled SO2 in Asthmatics. Environ Health Insights (2015) 0.84
Synergistic effect of various regulatory factors in TH1/TH2 balance; immunotherapeutic approaches in asthma. Int J Biomed Sci (2008) 0.84
A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy. Immun Inflamm Dis (2014) 0.83
Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol (2012) 0.83
Adjuvants for allergy vaccines. Hum Vaccin Immunother (2012) 0.82
Rapid polyclonal desensitization with antibodies to IgE and FcεRIα. J Allergy Clin Immunol (2013) 0.82
Biological toxicity and inflammatory response of semi-single-walled carbon nanotubes. PLoS One (2011) 0.81
Thymic Stromal Lymphopoietin Enhances Th2/Th22 and Reduces IL-17A in Protease-Allergen-Induced Airways Inflammation. ISRN Allergy (2013) 0.77
Regulatory T cells and the control of the allergic response. J Allergy (Cairo) (2012) 0.77
Generation of a chimeric dust mite hypoallergen using DNA shuffling for application in allergen-specific immunotherapy. Int J Clin Exp Pathol (2014) 0.77
Fel d 1-airway inflammation prevention and treatment by co-immunization vaccine via induction of CD4+CD25-Foxp3+ Treg cells. Hum Vaccin Immunother (2013) 0.77
Novel developments in the mechanisms of immune tolerance to allergens. Hum Vaccin Immunother (2012) 0.76
Diagnostic value of the basophil activation test in evaluating Hymenoptera venom sensitization. Wien Klin Wochenschr (2009) 0.76
Immunotherapy in all aspects. Eur Arch Otorhinolaryngol (2015) 0.76
Local nasal specific immunotherapy for allergic rhinitis. Allergy Asthma Clin Immunol (2006) 0.75
Allergy-associated T cell epitope repertoires are surprisingly diverse and include non-IgE reactive antigens. World Allergy Organ J (2014) 0.75
Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cells in vitro and in vivo. Mediators Inflamm (2009) 0.75
Can Serum-Specific IgE/Total IgE Ratio Predict Clinical Response to Allergen-Specific Immunotherapy in Children Monosensitized to House Dust Mite? J Allergy (Cairo) (2012) 0.75
[From the allergen-recognition by antibodies to new therapeutic concepts]. Wien Med Wochenschr (2008) 0.75
Subcutaneous and Sublingual Immunotherapy in Allergic Asthma in Children. Front Pediatr (2017) 0.75
Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest (2009) 4.10
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet (2005) 2.07
Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol (2003) 2.01
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87
Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol (2007) 1.85
Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol (2006) 1.68
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy (2009) 1.65
Tregs and allergic disease. J Clin Invest (2004) 1.64
Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J Allergy Clin Immunol (2011) 1.62
Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43
Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol (2008) 1.38
Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol (2013) 1.33
Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol (2005) 1.30
Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol (2007) 1.28
Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol (2010) 1.27
Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26
Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.26
Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 years. J Allergy Clin Immunol (2007) 1.22
Regulatory T cells and allergic disease. Inflamm Allergy Drug Targets (2008) 1.15
The CX3C chemokine fractalkine in allergic asthma and rhinitis. J Allergy Clin Immunol (2003) 1.13
Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. J Immunol (2007) 1.12
Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol (2005) 1.12
Mucosal immunity in asthma and chronic obstructive pulmonary disease: a role for immunoglobulin A? Proc Am Thorac Soc (2004) 1.09
Local allergic rhinitis: concept, pathophysiology, and management. J Allergy Clin Immunol (2012) 1.08
Allergen specificity of IgG(4)-expressing B cells in patients with grass pollen allergy undergoing immunotherapy. J Allergy Clin Immunol (2012) 1.08
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol (2007) 1.06
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clin Transl Allergy (2012) 1.04
Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods (2012) 1.04
The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods (2006) 1.03
Sub-lingual immunotherapy: world allergy organization position paper 2009. World Allergy Organ J (2009) 1.03
Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol (2011) 1.02
Local somatic hypermutation and class switch recombination in the nasal mucosa of allergic rhinitis patients. J Immunol (2003) 1.02
IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy. J Allergy Clin Immunol (2005) 1.01
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol (2003) 0.99
CCR4 in human allergen-induced late responses in the skin and lung. Eur J Immunol (2002) 0.99
Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol (2004) 0.98
IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy. Immunol Allergy Clin North Am (2006) 0.97
Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1. J Allergy Clin Immunol (2007) 0.96
IL-22 suppresses IFN-γ-mediated lung inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 0.96
Germinal-centre reactions in allergic inflammation. Trends Immunol (2006) 0.95
Allergen immunotherapy and tolerance. Allergol Int (2013) 0.92
NHS allergy services in the UK: proposals to improve allergy care. Clin Med (2002) 0.91
One hundred years of allergen immunotherapy: time to ring the changes. J Allergy Clin Immunol (2011) 0.90
Allergen immunotherapy for house dust mite: clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther (2013) 0.90
Biased use of VH5 IgE-positive B cells in the nasal mucosa in allergic rhinitis. J Allergy Clin Immunol (2005) 0.89
Serum immunologic markers for monitoring allergen-specific immunotherapy. Immunol Allergy Clin North Am (2011) 0.88
Adjuvants for allergen immunotherapy: experimental results and clinical perspectives. Curr Opin Allergy Clin Immunol (2004) 0.87
Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med (2002) 0.86
Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res (2006) 0.85
The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: a Global Allergy and Asthma European Network (GA(2)LEN) article. J Allergy Clin Immunol (2010) 0.84
Peptide-induced immune regulation by a promiscuous and immunodominant CD4T-cell epitope of Timothy grass pollen: a role of Cbl-b and Itch in regulation. Thorax (2013) 0.83
CXCR1+CD4+ T cells in human allergic disease. J Immunol (2004) 0.83
Postnasal drip and chronic cough: An open interventional study. Respir Med (2009) 0.82
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses. J Allergy Clin Immunol (2012) 0.82
Tobacco industry lobbyists and their health-care clients. Lancet (2013) 0.82
Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. J Allergy Clin Immunol (2012) 0.81
Mechanisms of sublingual immunotherapy. Immunol Allergy Clin North Am (2011) 0.81
Immunological responses to allergen immunotherapy. Clin Allergy Immunol (2004) 0.81
Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol (2013) 0.80
Allergen immunotherapy for allergic respiratory diseases. Hum Vaccin Immunother (2012) 0.79
Local IgE synthesis in allergic rhinitis and asthma. Curr Allergy Asthma Rep (2002) 0.78
Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE). Clin Transl Allergy (2013) 0.77
Rhinitis with negative skin tests and absent serum allergen-specific IgE: more evidence for local IgE? J Allergy Clin Immunol (2009) 0.77
Immunomodulatory treatment strategies for allergic diseases. Curr Drug Targets Inflamm Allergy (2003) 0.76
Sublingual immunotherapy for allergic Rhinoconjunctivitis, allergic asthma, and prevention of allergic diseases. Clin Allergy Immunol (2008) 0.76
Perennial rhinitis. BMJ (2007) 0.75
Treatment of seasonal allergic rhinitis: desensitisation for hay fever works. BMJ (2003) 0.75
Levocetirizine improves health-related quality of life and health status in persistent allergic rhinitis. Respir Med (2006) 0.75
Tradition and innovation: finding the right balance. J Allergy Clin Immunol (2007) 0.75
Allergen injection immunotherapy. Clin Allergy Immunol (2002) 0.75
Biomarkers of tolerance in response to allergen immunotherapy. Arb Paul Ehrlich Inst Bundesinstitut Impfstoffe Biomed Arzneim Langen Hess (2013) 0.75
Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol (2008) 0.75
Silk contact anaphylaxis. Contact Dermatitis (2014) 0.75